If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
1 |
Names of Reporting Persons.
OrbiMed Advisors LLC |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o |
|
3 |
SEC Use Only
|
4 |
Source of Funds (See Instructions)
|
5 |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)
or 2(e)
|
o |
6 |
Citizenship or Place of Organization
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
Sole Voting Power
0 |
8 |
Shared Voting Power
3,044,753 (1) |
9 |
Sole Dispositive Power
0 |
10 |
Shared Dispositive Power
3,044,753 (1) |
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person
3,044,753 (1) |
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
|
o |
13 |
Percent of Class Represented by Amount in Row (11)
12.2% (2) |
14 |
Type of Reporting Person (See Instructions)
IA |
|
|
|
|
|
| (1) | This total consists of: (i) 1,738,066 shares of the common stock (the “Common
Stock”) of Sierra Oncology, Inc. (the “Issuer”) and (ii) 1,306,687 shares of Common Stock issuable upon the
exercise of Series A warrants. |
| (2) | This
percentage is calculated based upon 23,665,100 shares of Common Stock outstanding, as set
forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on March 10, 2022 and giving effect to the additional
1,306,687 shares of Common Stock that would be outstanding
following the exercise of Series A warrants as reported above. |
1 |
Names of Reporting Persons.
OrbiMed Capital GP VII LLC |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o |
|
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions)
|
5 |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) |
o |
6 |
Citizenship or Place of Organization
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
Sole Voting Power
0 |
8 |
Shared Voting Power
2,647,612 (1) |
9 |
Sole Dispositive Power
0 |
10 |
Shared Dispositive Power
2,647,612 (1) |
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,647,612 (1) |
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |
o |
13 |
Percent of Class Represented by Amount in Row (11)
10.7% (2) |
14 |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
|
| (1) | This total consists of: (i) 1,511,362 shares of the common stock (the “Common
Stock”) of Sierra Oncology, Inc. (the “Issuer”) and (ii) 1,136,250 shares of Common Stock issuable upon the
exercise of Series A warrants. |
| (2) | This
percentage is calculated based upon 23,665,100 shares of Common Stock outstanding, as set
forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on March 10, 2022 and giving effect to the additional
1,136,250 shares of Common Stock that would be outstanding
following the exercise of Series A warrants as reported above. |
1 |
Names of Reporting Persons.
OrbiMed Genesis GP LLC |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o |
|
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions)
|
5 |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) |
o |
6 |
Citizenship or Place of Organization
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
Sole Voting Power
397,141 (1) |
8 |
Shared Voting Power
|
9 |
Sole Dispositive Power
397,141 (1) |
10 |
Shared Dispositive Power
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person
397,141 (1) |
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |
o |
13 |
Percent of Class Represented by Amount in Row (11)
1.7% (2) |
14 |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
|
| (1) | This total consists of: (i) 226,704 shares of the common stock (the “Common
Stock”) of Sierra Oncology, Inc. (the “Issuer”) and (ii) 170,437 shares of Common Stock issuable upon the
exercise of Series A warrants. |
| (2) | This
percentage is calculated based upon 23,665,100 shares of Common Stock outstanding, as set
forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on March 10, 2022 and giving effect to the additional
170,437 shares of Common Stock that would be outstanding
following the exercise of Series A warrants as reported above. |
CUSIP No. 82640U 10 7 |
|
|
|
|
|
|
|
|
1 |
Names of Reporting Persons.
OrbiMed Capital LLC |
|
2 |
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o |
|
|
3 |
SEC Use Only |
|
4 |
Source of Funds (See Instructions)
|
|
5 |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e)
|
o |
|
6 |
Citizenship or Place of Organization
Cayman Islands |
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
Sole Voting Power
397,141 (1) |
|
8 |
Shared Voting Power
0 |
|
9 |
Sole Dispositive Power
397,141 (1) |
|
10 |
Shared Dispositive Power
0 |
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person
397,141 (1) |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
|
o |
|
13 |
Percent of Class Represented by Amount in Row (11)
1.7%* |
|
14 |
Type of Reporting Person (See Instructions)
IA |
|
|
|
|
|
|
|
|
|
| (1) | This total consists of: (i) 226,704 shares of the common stock (the “Common
Stock”) of Sierra Oncology, Inc. (the “Issuer”) and (ii) 170,437 shares of Common Stock issuable upon the
exercise of Series A warrants. |
| (2) | This percentage is calculated based upon 23,665,100 shares of Common Stock outstanding, as set forth
in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 10, 2022
and giving effect to the additional 170,437 shares of Common Stock that would be outstanding following
the exercise of Series A warrants as reported above. |
Item 1. Security and Issuer
This Amendment No. 3 to Schedule
13D (the “Statement”) supplements and amends the Statement of Schedule 13D of OrbiMed Advisors LLC, OrbiMed Capital
GP VII LLC, OrbiMed Global Healthcare GP LLC (“OrbiMed Global Healthcare”), and OrbiMed Capital LLC originally filed
with the Securities and Exchange Commission (the “SEC”) on November 27, 2019 and amended by Amendment No. 1 thereto
filed with the SEC on November 5, 2021 (“Amendment No. 1”) and Amendment No. 2 thereto filed with the SEC
on February 2, 2022 (“Amendment No. 2”). The Statement relates to the common stock, par
value $0.001 per share (the “Shares”) of Sierra Oncology, Inc., a corporation organized under the laws of Delaware
(the “Issuer”), with its principal executive offices located at 885 West Georgia Street, Suite 2150, Vancouver, BC
V6C 3E8. The Shares are listed on the NASDAQ Global Market under the ticker symbol “SRRA”. Information given in response
to each item shall be deemed incorporated by reference in all other items, as applicable.
The Reporting Persons are filing
this Amendment No. 3 to report a decrease in the percentage of the total number of outstanding Shares of the Issuer beneficially owned
by the Reporting Persons due to an increase in the total number of outstanding Shares of the Issuer as reported on the Issuer’s
Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2. Identity and Background
(a) This Schedule 13D is being
filed by OrbiMed Advisors LLC (“OrbiMed Advisors”), OrbiMed Capital GP VII LLC (“OrbiMed GP”), OrbiMed
Genesis GP LLC (“Genesis GP”), and OrbiMed Capital LLC (“OrbiMed Capital”) (collectively, the “Reporting
Persons”).
(b) — (c), (f) OrbiMed
Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers
Act of 1940, as amended, is the managing member or general partner of certain entities as more particularly described in Item 6 below.
OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
OrbiMed GP, a limited liability company organized under
the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below. OrbiMed GP
has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
Genesis GP, a limited liability company organized under
the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below. Genesis GP
has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
OrbiMed Capital, a limited liability
company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended,
is the investment adviser of certain entities as more particularly described in Item 6 below. OrbiMed Capital has its principal
offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
The directors and executive officers
of OrbiMed Advisors, OrbiMed Capital, OrbiMed GP, and Genesis GP are set forth on Schedules I, II, III and IV, respectively, attached
hereto. Schedules I, II, III and IV set forth the following information with respect to each such person:
(i) name;
(ii) business
address;
(iii) present
principal occupation of employment and the name, principal business and address of any corporation or other organization in which such
employment is conducted; and
(iv) citizenship.
(d) — (e) During the last
five years, neither the Reporting Persons nor any Person named in Schedules I through IV has been (i) convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
Not applicable.
Item 4. Purpose of Transaction
The Shares were initially acquired
by the Reporting Persons for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the
Issuer’s business on behalf of the Reporting Persons’ respective advisory clients.
The Reporting Persons from time
to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial
condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those
for the Issuer’s Shares in particular, as well as other developments and other investment opportunities. Based upon such review,
the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances
existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because
of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in
privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose
of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open
market or in privately negotiated transactions.
Except as set forth in this Schedule 13D, the Reporting
Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional
securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets
of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any
plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in
the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate
structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may
impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered
or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered
national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant
to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer
(a) — (b) The following
disclosure is based upon 23,665,100 outstanding Shares of the Issuer, as set forth in the Issue’s Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 10, 2022 and giving effect to an additional 1,477,124 Shares that may be issued upon
the exercise of Series A Warrants.
As of the date of this filing,
OPI VII, a limited partnership organized under the laws of Delaware, holds 1,511,362 Shares and is the beneficial owner of an additional
1,136,250 Shares that may be issued upon the exercise of Series A Warrants. Such Shares constitute approximately 10.7% of the issued and
outstanding Shares. OrbiMed GP is the general partner of OPI VII, pursuant to the terms of the limited partnership agreement of
OPI VII, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of
OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI
VII and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares
held by OPI VII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L.
Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
As of the date of this filing,
Genesis, a limited partnership organized under the laws of the Cayman Islands, holds 226,704 Shares and is the beneficial owner of an
additional 170,437 Shares that may be issued upon the exercise of Series A Warrants. Such Shares constitute approximately 1.7% of the
issued and outstanding Shares. Genesis GP is the general partner of Genesis, pursuant to the terms of the limited partnership agreement
of Genesis, and OrbiMed Advisors is the managing member of Genesis GP, pursuant to the terms of the limited liability company agreement
of Genesis GP. As a result, OrbiMed Advisors and Genesis GP share power to direct the vote and disposition of the Shares held by
Genesis and may be deemed, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the
Shares held by Genesis. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl
L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.
As of the date of this filing,
OPM, an exempted company organized under the laws of Bermuda, holds 226,704 Shares and is the beneficial owner of an additional 170,437
Shares that may be issued upon the exercise of Series A Warrants. Such Shares constitute approximately 1.7% of the issued and outstanding
Shares. OrbiMed Capital is the investment advisor of OPM. As a result, OrbiMed Capital has the power to direct the vote and disposition
of the Shares held by OPM and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner
of the Shares held by OPM. OrbiMed Capital disclaims any beneficial ownership over the shares of the other Reporting Persons.
OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho,
and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
(c) Other than as described in
Amendment No. 2, the Reporting Persons have not effected any transactions during the past sixty (60) days in any Shares.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to Securities of the Issuer
The
terms and provisions of the Series A Warrants are qualified by the full text of the Series A Warrant, which is filed as Exhibit 2 to this
Statement and incorporated herein by reference.
Mona Ashiya (“Ashiya”),
an employee of OrbiMed Advisors, is a member of the Board of Directors of the Issuer and, accordingly, OrbiMed Advisors and OrbiMed GP
may have the ability to affect and influence control of the Issuer. From time to time, Ashiya may receive stock options or other awards
of equity-based compensation pursuant to the Issuer’s compensation arrangements for non-employee directors. Pursuant to an agreement
with OrbiMed Advisors and OrbiMed GP, Ashiya is obligated to transfer any securities issued under any such stock options or other awards,
or the economic benefit thereof, to OrbiMed Advisors and OrbiMed GP, which will in turn ensure that such securities or economic benefits
are provided to OPI VII.
Lock-up Agreement
In connection with the Issuer’s public offering
completed on January 31, 2022 (the “Offering”), OPI VII, Genesis, OPM and Ashiya entered into a lockup agreement (the
“Lock-up Agreement”) with the Issuer’s underwriters pursuant to which, among other things, each of these stockholders
agreed not to, except in limited circumstances, directly or indirectly (i) sell, offer to sell, contract to lend, pledge, hypothecate,
grant any security interest in, transfer or dispose of any Shares, and (ii) effect any short sale, establish or increase any “put
equivalent position” or liquidate or decrease any “call equivalent position” with respect to any Shares, or otherwise
enter into any swap, derivative or other transaction or arrangement that transfers to another, in whole or in part, any economic risk
of ownership of a Share, whether or not such transaction is to be settled by delivery of Shares, other securities, cash or other consideration,
from the date of the final prospectus supplement for the Offering until 90 days from the date of the final prospectus supplement for the
Offering.
The foregoing description of the Lock-up Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of Lock-up Agreement, a copy
of which is filed as Exhibit 3 and incorporated herein by reference.
Item 7. Material to Be Filed as Exhibits
Exhibit |
Description |
1. |
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC. |
2. |
Form Series A Warrant to Purchase Common Stock (filed as Exhibit 4.1 to the Issuer’s current report on Form 8-K as filed with the Commission on November 7, 2019 (SEC File No. 333-225650) and incorporated herein by reference). |
3 |
Form of Lock-Up Agreement (filed as Exhibit 99.3 to the Reporting
Persons’ Schedule 13D/A as filed with the Commission on February 2, 2022 and incorporated herein by reference). |
Signature
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 15, 2022 |
ORBIMED ADVISORS LLC |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Carl L. Gordon |
|
|
|
Name: Carl L. Gordon |
|
|
|
Title: Member |
|
|
|
|
|
|
ORBIMED CAPITAL GP VII LLC |
|
|
|
|
|
|
By: |
ORBIMED ADVISORS LLC, its managing member |
|
|
|
|
|
By: |
/s/ Carl L. Gordon |
|
|
|
Carl L. Gordon |
|
|
|
Title: Member of OrbiMed Advisors LLC
|
|
|
ORBIMED GENESIS GP LLC |
|
|
|
|
|
By: ORBIMED ADVISORS LLC, its managing member |
|
|
|
|
|
By: |
/s/ Carl L. Gordon |
|
|
|
Carl L. Gordon |
|
|
|
Title: Member of OrbiMed Advisors LLC
|
|
|
|
|
|
ORBIMED CAPITAL LLC |
|
|
|
|
|
|
By: |
/s/ Carl L. Gordon |
|
|
|
Carl L. Gordon |
|
|
|
Title: Member |
|
SCHEDULE I
The
names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below. Unless
otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th
Floor, New York, NY 10022.
Name |
Position with Reporting Person |
Principal Occupation |
|
|
|
|
|
|
Carl L. Gordon |
Member |
Member
OrbiMed Advisors LLC |
|
|
|
Sven H. Borho
German and Swedish Citizen |
Member |
Member
OrbiMed Advisors LLC |
|
|
|
|
|
|
W. Carter Neild |
Member |
Member
OrbiMed Advisors LLC |
|
|
|
Geoffrey C. Hsu |
Member |
Member
OrbiMed Advisors LLC |
|
|
|
C. Scotland Stevens
|
Member |
Member
OrbiMed Advisors LLC
|
David P. Bonita |
Member |
Member
OrbiMed Advisors LLC
|
Peter A. Thompson |
Member |
Member
OrbiMed Advisors LLC
|
Matthew S. Rizzo |
Member |
Member
OrbiMed Advisors LLC
|
Trey Block |
Chief Financial Officer
|
Chief Financial Officer
OrbiMed Advisors LLC |
SCHEDULE II
The
names and present principal occupations of each of the executive officers and directors of OrbiMed Capital LLC are set forth below. Unless
otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th
Floor, New York, NY 10022.
Name |
Position with Reporting Person |
Principal Occupation |
|
|
|
Carl L. Gordon |
Member |
Member
OrbiMed Capital LLC |
|
|
|
Sven H. Borho
German and Swedish Citizen |
Member |
Member
OrbiMed Capital LLC |
|
|
|
W. Carter Neild |
Member |
Member
OrbiMed Capital LLC |
|
|
|
Geoffrey C. Hsu |
Member |
Member
OrbiMed Capital LLC |
|
|
|
C. Scotland Stevens
David P. Bonita |
Member
Member |
Member
OrbiMed Capital LLC
Member
OrbiMed Capital LLC
|
Peter A. Thompson |
Member |
Member
OrbiMed Capital LLC
|
Matthew S. Rizzo |
Member |
Member
OrbiMed Capital LLC
|
Trey Block |
Chief Financial Officer
|
Chief Financial Officer
OrbiMed Capital LLC |
SCHEDULE III
The business
and operations of OrbiMed Capital GP VII LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors
LLC, set forth in Schedule I attached hereto.
SCHEDULE IV
The business
and operations of OrbiMed Genesis GP LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors
LLC, set forth in Schedule I attached hereto.
EXHIBIT INDEX
Exhibit |
Description |
1. |
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC. |
2. |
Form Series A Warrant to Purchase Common Stock (filed as Exhibit 4.1 to the Issuer’s current report on Form 8-K as filed with the Commission on November 7, 2019 (SEC File No. 333-225650) and incorporated herein by reference). |
3 |
Form of Lock-Up Agreement (filed as Exhibit 99.3 to the Reporting Persons’ Schedule 13D/A as filed with the Commission on February 2, 2022 and incorporated herein by reference). |